A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint

Rui-Hong Wang*, Hongtao Yu†, and Chu-Xia Deng**

*National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10/9N105, Bethesda, MD 20892; and †Department of Pharmacology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9041

Communicated by Philip Leder, Harvard Medical School, Boston, MA, October 15, 2004 (received for review July 1, 2004)

BRCA1-associated breast cancer exhibits significantly higher levels of chromosomal abnormalities than sporadic breast cancers. However, the molecular mechanisms regarding the roles of BRCA1 in maintaining genome integrity remain elusive. By using a mouse model deficient for Brca1 full-length isoform (*Brca1*^{Δ11/Δ11}), we found that *Brca1*^{Δ11/Δ11} cells displayed decreased expression of a number of genes that are involved in the spindle checkpoint, including Mad2, which is a key component of spindle checkpoint that inhibits anaphase-promoting complex. We showed that *Brca1*^{Δ11/Δ11} cells failed to arrest at metaphase in the presence of nocodazole and underwent apoptosis because of activation of p53. Consistently, reconstitution of Mad2 in *Brca1*^{Δ11/Δ11} cells partially restored the spindle checkpoint and attenuated apoptosis. By using UBR60 cells, which carry tetracycline-regulated expression of BRCA1, we demonstrated that BRCA1 binds to transcription factor OCT-1 and up-regulates the transcription of MAD2. Furthermore, we showed that the induction of BRCA1 to endogenous MAD2 or transfected MAD2 luciferase reporter in UBR60 cells was completely inhibited by acute suppression of BRCA1 by RNA interference. These data reveal a role of BRCA1 in maintaining genome integrity by interplaying with p53 and genes that are involved in the spindle checkpoint and apoptosis.

Mad2 | p53 | cell cycle | OCT-1 | genetic instability

The spindle checkpoint ensures the astonishing accuracy of chromosome segregation by preventing cells with unaligned chromosomes from exiting mitosis. The molecular components of the spindle checkpoint include at least two evolutionarily conserved protein families, Mad and Bub (1, 2). It was shown that Mad2 binds selectively to unattached kinetochores and is capable of inhibiting anaphase-promoting complex together with BubR1 (3, 4). Consistently, microinjection of Mad2 antibodies yields premature anaphase onset and chromosome missegregation (5). Absence of Mad2 in mouse embryos resulted in accumulation of mitotic errors and apoptosis, leading to early lethality at embryonic day 5 (E5)–E6, whereas haploinsufficiency of Mad2, which produces ≈30% less Mad2 protein, provokes lung tumors after a long latency period (6, 7). Despite the essential role of Mad2 in the spindle checkpoint, it is unclear how the expression of Mad2 is regulated.

Ample experimental evidence indicates that BRCA1 plays essential roles in maintaining genome integrity (8–10). It has been shown that mouse embryos carrying targeted disruptions of *Brca1* died at early embryonic developmental stages because of p53-mediated apoptosis triggered by genetic instability (11, 12). Consistently, haploid loss of p53 suppresses the embryonic lethality caused by targeted deletion of *Brca1* exon 11 (*Brca1*^{Δ11/Δ11}) and allows mutant mice survive to adulthood, exhibiting increased tumorigenesis and chromosome abnormalities (13, 14). These observations are consistent with findings that a significantly higher percentage of BRCA1-associated breast cancer than sporadic cancers contained p53 mutations (15). Paradoxically, the *Brca1*^{Δ11/Δ11} mouse embryonic fibroblast (MEF) cells exhibited slow growth, fast speed to reach senescence, and the accumulation of aneuploidy (13, 16), suggesting that these cells had undergone abnormal mitosis.

BRCA1 has been shown to associate with many cell-cycle proteins (17). During late G₁ and S phases, BRCA1 protein increases and becomes phosphorylated. Upon exiting from M phase, BRCA1 is dephosphorylated and its expression decreases (18, 19). This expression pattern prompted intensive studies of BRCA1 in cell-cycle checkpoints, leading to the discoveries of its important roles in centrosome duplication as well as G₂/M and S checkpoints (13, 20). However, a role of BRCA1 in the spindle checkpoint is undetermined. Here, we address this issue by using the following three experimental systems: *Brca1* mutant MEFs; Cre-loxP, or small interfering RNA-mediated acute *Brca1*-deletion cell models; and UBR60 cells carrying tet-off regulated BRCA1 expression (21).

Materials and Methods

Cell Culture and Treatment. Primary MEF cells were derived from E14.5 embryos by using a standard procedure. UBR60 cells were cultured in DMEM supplemented with 10% FBS in the presence or absence of 1 μg/ml tetracycline (21). Plasmids bearing GFP-MAD2 or GFP were transfected into *Brca1*^{Δ/Δ} cells by using Lipofectamine 2000 (Invitrogen). To generate acute *Brca1* exon 11-deletion cell lines, linearized pCRE-ERT2 (22) and *neo* (23) plasmids were cotransfected into *Brca1*^{Co/Δ} cells. For synchronization, the cells were starved with 0.25% serum, released into culture medium supplemented with 100 ng/ml nocodazole (Sigma), and harvested at 0, 12, 24, 36, 48, and 60 h.

Fluorescence-Activated Cell Sorting (FACS) and Immunofluorescence Analysis. After being fixed with 70% ethanol, the cells were stained with phosphorylated histone H3 Ab (Upstate Biotechnology, Lake Placid, NY) and propidium iodide (Sigma) before being loaded onto the FACSCalibur (Becton Dickinson). To check the lagging chromosome, MEF cells were fixed with methanol. Anti-α-tubulin Ab (Sigma) was applied. Alexa 546-anti-mouse IgG (Molecular Probes) plus 100 ng/ml DAPI (Molecular Probes) was then incubated with cells. Images were captured with a DMRBE epifluorescent microscope (Leica, Deerfield, IL) equipped with a charge-coupled device (CCD) camera (Olympus Megafire, Opelco, Dulles, VA).

Annexin-V-FITC Apoptosis Analysis. Cells were treated with nocodazole for 24 and 36 h. Mitotic shake-off was performed. Mitotic cells were stained with annexin V-EGFP (Clontech). Positive cells were scored under fluorescent microscope. However, the entire cell population was incubated with annexin V-EGFP and analyzed with the FACSCalibur system.

Mitotic Index Analysis. Unsynchronized *Brca1*^{Co/Δ}CRE-ERT2 clones, parental *Brca1*^{Co/Δ} cells, and WT-CRE-ERT2 cells were grown on chamber slides in the presence or absence of 1 μM 4-hydroxytamoxifen (4-HT) for 0, 1, 2, 3, 4, 5, 6, 7, and 8 days. At

Abbreviations: MEF, mouse embryonic fibroblast; 4-HT, 4-hydroxytamoxifen; En, embryonic day *n*; FACS, fluorescence-activated cell sorting; ChIP, chromatin immunoprecipitation; RNAi, RNA interference.

†To whom correspondence should be addressed. E-mail: chuxiad@bdg10.niddk.nih.gov.

© 2004 by The National Academy of Sciences of the USA

each time point, 100 ng/ml nocodazole was added into the culture for a further 12-h incubation. The cells were stained with DAPI. Mitotic index was determined by scoring $\geq 1,000$ cells under a fluorescent microscope (Olympus 1 $\times$ 81, Opelco).

Western Blotting and Immunoprecipitation. Western blot analysis was accomplished by enhanced chemiluminescence detection (Amersham Biosciences). The following antibodies were used: BRCA1 Ab-1 (Oncogene Science), OCT1, cyclin B1, Cdc2 (Santa Cruz Biotechnology), Mad2 (Novus Biologicals, Littleton, CO), Bax (BD Pharmingen), and HRP goat anti-rabbit or mouse IgG (H+L) (Kirkegaard & Perry Laboratories). Nuclear proteins from UBR60 cells were immunoprecipitated with BRCA1 and OCT1 antibodies. The immunoprecipitated complex was analyzed with 8% Novex Tris-glycine gel (Invitrogen).

RT-PCR and TaqMan-PCR Analyses. Total RNA was extracted from embryos or MEF cells. Reverse-transcription reactions were carried out with the First-strand cDNA synthesis kit (Roche). The optimal number of cycles for amplification varies from 22 to 31. The real-time PCR was performed with ABI PRISM 7000 sequence-detection system (Applied Biosystems).

Chromatin Immunoprecipitation (ChIP) Assay. ChIP assays were performed as described (24). Cells were cross-linked with 1% formalin. DNA is extracted from immunoprecipitates of BRCA1 Ab. For PCR, 2 μ l from 30 μ l of DNA extraction and VENT polymerases (Biolabs, Northbrook, IL) were used.

Human MAD2 Promoter Analysis. The fragment containing 5'-regulatory sequence of human MAD2 promoter (base pairs 1,333–2,421, the translation-initiation codon is at 2,338) was cloned into PGL3-Basic vector (Promega). UBR60 cells were transfected with the plasmids and renilla luciferase pRL-TK vector (Promega). Luciferase analysis was performed with Dual-Luciferase reporter-assay system (Promega). Serial deletions were made to search for basal promoter and BRCA1-inducible activity. Point mutations of OCT1 site in fragment of base pairs 2,096–2,297 were done by using the QuickChange site-directed mutagenesis kit (Stratagene).

Biotin-Streptavidin Pull-Down Assay. Three oligonucleotides containing biotin on the 5' nucleotide of the sense strand were used in the pull-down assays. We incubated 1 μ g of each double-stranded oligonucleotide with 300 μ g of nuclear protein for 20 min at room temperature. We added 30 μ l of poly(dI-dC) preabsorbed streptavidin-agarose beads for 4 h at 4°C. The protein-DNA-streptavidin-agarose complex was analyzed with SDS/PAGE. For more information, see *Supporting Materials and Methods*, which is published as supporting information on the PNAS web site.

Results

Brca1 $\Delta 11/\Delta 11$ Cells Exhibited Abnormal Chromosomal Behavior During Mitosis and Were Defective in the Spindle Checkpoint. Analyzing *Brca1 $\Delta 11/\Delta 11$* MEF cells at passage 2, we found that $\approx 29\%$ (58/200) of these cells displayed lagging chromosome in metaphase, anaphase, and telophase (Fig. 1A). This abnormality was not observed in >230 examined WT mitotic cells (Fig. 1B). Because all of the MEF cells were derived from E14.5 embryos and had been cultured for at least 3 days before analysis, it is possible that this phenotype was not a direct consequence of the *Brca1* mutation. To rule out this possibility, we established a conditional mutant cell model (*Brca1^{Col} Δ*) to achieve acute deletion of *Brca1* exon 11 by using a 4-HT-inducible Cre-LoxP system (see Fig. 7, which is published as supporting information on the PNAS web site). By analyzing several clones carrying acute deletion of *Brca1* exon 11 (*Brca1^{Col} Δ* Cre-ERT2), we observed similar abnormal chromosome behavior shown in Fig. 1, indicating that these defects were linked directly to the *Brca1* deficiency.

Fig. 1. Chromosome lagging and spindle-checkpoint defects associated with *Brca1* deficiency during mitosis. (A and B) Images of *Brca1 $\Delta 11/\Delta 11$* (A) and WT (B) MEF cells at passage 2 stained with DAPI and anti- α -tubulin Ab. Arrows indicate lagging chromosomes. (C) Mitotic index of cells upon nocodazole treatment. Cre-inducible clones (*Brca1^{Col} Δ* Cre-ERT2), parental cells (*Brca1^{Col} Δ*), and Cre-inducible WT cells (WT-CRE-ERT2) were grown in the presence of tamoxifen, and nocodazole was added at the indicated time points. At 12 h later, cells were harvested and scored for mitotic index. A steady decline in mitotic index was observed in all three tested inducible clones as the treatment of 4-HT (deletion of *Brca1*) proceeded at 12–96 h. Presence of 4-HT did not alter the response of parental and WT cells to nocodazole-induced mitotic arrest.

It has been shown that a single unattached kinetochore is sufficient to activate the spindle checkpoint (25). Thus, the abnormal chromosome behavior in *Brca1 $\Delta 11/\Delta 11$* cells suggests that the spindle checkpoint was defective. To verify this phenotype, we treated *Brca1^{Col} $\Delta 11$* Cre-ERT2 cells in the presence or absence of 4-HT with nocodazole, which is a reagent that depolymerizes microtubules and activates the spindle checkpoint. Parental cells (*Brca1^{Col} Δ*) and Cre-expressing WT cells (WT-CRE-ERT2) were also treated as controls. Our data indicated that $\approx 52\%$ of *Brca1^{Col} $\Delta 11$* Cre-ERT2 cells were arrested at metaphase 12 h after the nocodazole treatment. The mitotic index of these cells declined dramatically over time after 4-HT treatment (Fig. 1C). In contrast, control cells showed similar mitotic index ($\approx 60\%$) at all of the time points. These data indicate that, after acute deletion of the conditional allele of *Brca1*, *Brca1^{Col} $\Delta 11$* Cre-ERT2 cells did not undergo metaphase arrest and continued to progress through the cell cycle. A failure to undergo metaphase arrest induced by nocodazole or colcemid was also observed in primary and immortalized *Br $\Delta 11/\Delta 11$* MEF cells (data not shown).

However, the above experiments did not rule out the possibility that *Brca1 $\Delta 11/\Delta 11$* cells underwent a profound growth arrest before

Fig. 3. p53 deficiency suppresses apoptosis in *Brca1*^{Δ11/Δ11} cells. (A and B) p53 deficiency suppressed apoptosis of *Brca1*^{Δ11/Δ11} cells and allowed accumulation of polyploid cells. (C) Western blot analysis to compare p53 and p21 levels between WT and *Brca1*^{Δ11/Δ11} cells.

able to confirm the hyperactivity of p53 in *Brca1*^{Δ11/Δ11} cells but not in control cells (Fig. 3C).

Decreased Mad2 Expression in *Brca1*^{Δ11/Δ11} Embryos and MEFs. Our screening of candidate genes also revealed decreased expression of several genes that are known to be involved in the spindle checkpoint, including Bub1, BubR1, Polo-like kinase, ZW-10, and Mad2 (Fig. 4A). We chose to study Mad2 further because of its demonstrated importance in the spindle checkpoint (2, 30). Our analysis revealed that *Mad2* was significantly down-regulated in *Brca1*^{Δ11/Δ11} mutant embryos compared with WT controls at developmental stages E13.5–E18.5 (Fig. 4B and C). Furthermore, acute deletion of *Brca1* exon11 in inducible clone (clone 217) led to significant reduction of *Mad2* 48–60 h after addition of 4-HT (Fig. 4D). Decreased expression of *Mad2* mRNA also led to decreased Mad2 protein levels, as determined by Western blot analysis (data not shown).

BRCA1 Up-Regulates Mad2 Expression by Binding to Its Promoter. Next, we tested whether *Brca1* might serve as a positive regulator of *Mad2* by using UBR60 cells, which carry a tet-off controlled human *BRCA1* (21). After withdrawing tetracycline for 24 h, we detected an increase in the *BRCA1* protein level, which continued to increase through 48 and 72 h (Fig. 4E). At the same time, *MAD2* protein level was elevated by ≈1.7- and 2.2-fold at 48 and 72 h after induction, respectively. RT-PCR analysis revealed that induced expression of *BRCA1* increased the mRNA levels of *MAD2* (Fig. 4F). These data suggest that *BRCA1* is capable of up-regulating the expression levels of *MAD2*.

To address the relationship between *BRCA1* and *MAD2* further, ChIP assay with a *BRCA1* Ab was performed. PCR assays using the primers that cover 2,421 bp of the 5' regulatory region of the *MAD2* promoter in UBR60 cells under inducible condition (without tetracycline) showed that *BRCA1* bound to four regions (i.e., 116–619, 599–1,046, 1,025–1,354, and 1,681–2,161) of the *MAD2* promoter (Fig. 4G). Of note, we found that, in the noninducible condition (with tetracycline), the endogenous *BRCA1* also interacted with the *MAD2* promoter, albeit with reduced intensities as revealed by PCR (Fig. 4G). These data indicate that *BRCA1* binds to the promoter of *MAD2* in a dosage dependent manner. The endogenous *BRCA1* could interact with the promoter of *MAD2*

Fig. 4. *BRCA1* positively regulates *MAD2* by interacting with its promoter. (A) RT-PCR array of gene expression in *Brca1* mutant and control primary MEF cells. (B and C) *Mad2* expression in E13.5–E18.5 embryos revealed by RT-PCR (B) and by TaqMan PCR (C). Expression of Wt embryos were set at 1. (D) RT-PCR analysis of *Mad2* expression in *Brca1* inducible (clone 217) and noninducible (clone 29) knockout cells in the presence of 4-HT at 0–60 h. (E and F) *BRCA1* positively regulate *MAD2* in UBR60 cells, as revealed by Western blotting (E) and RT-PCR (F). The relative intensities of bands (normalized with the loading control) were quantified by using QUANTITY ONE software (Bio-Rad). (G) ChIP assay to show *BRCA1* binds to *MAD2* promoter in UBR60 cells 48 h in the presence or absence of tet. *BRCA1* binds to the following four regions: base pairs 116–619, 599–1,046, 1,025–1,354, and 1,681–2,161. The starting translation codon is at 2,338 (*Mad2*; GenBank accession no. AB056160). We have also used the same condition to test another promoter (*SOX9*, last row), and we could not detect any obvious binding.

was also confirmed in MCF-7 cells (Fig. 9A, which is published as supporting information on the PNAS web site).

To define the minimal *MAD2* promoter that contains the essential regulatory element that interacts with *BRCA1*, we subcloned a DNA fragment including nucleotides 1,333–2,421, which contains one potential *BRCA1* interaction site, into a luciferase reporter, pGL3B. Testing serial deletion constructs in UBR60 cells, we found that the element that responds to *BRCA1* induction is located between nucleotides 2,096–2,297 (Fig. 5A). We next used MATINSPECTOR (version 2.2), which is a program that identifies potential DNA-protein interacting sites, to search these 201 nucleotides and identified four nucleotides (2,141–2,144; ACAT), a potential binding motif for the transcription factor OCT1 (Fig. 5B). Next, we tested whether an oligonucleotide containing this site (WT, Fig. 5B) could bind to *BRCA1* by a pull-down assay using biotin-labeled oligonucleotides. Our data indicated that the WT oligonucleotide, but not its mutant forms (MT-1 and MT-2, Fig. 5B), bound to *BRCA1* (Fig. 5C). Of note, we found that the WT, but not the mutant oligonucleotides, could also pull down OCT1 (Fig. 5C), suggesting a potential interaction between *BRCA1* and OCT1. To confirm this result, we performed reciprocal immunoprecipitation and demonstrated that *BRCA1* and OCT1 indeed interacted with each other in UBR60 cells (Fig. 5D). We also performed these experiments in MCF-7 cells, and our data indi-

Fig. 5. BRCA1 interacts with MAD2 promoter and positively regulates its function. (A) Luciferase reporter assay of constructs generated by serial deletion. (B) WT and two mutant oligonucleotides from nucleotides 2,131–2,161. The putative OCT1 core like sequence is marked with underlying astral. (C) Biotin-streptavidin pull-down assay. We incubated 1 μ g each Biotin labeled oligonucleotide with 300- μ g extracts from UBR60 cells 48 h after withdraw of tetracycline. (D) Coimmunoprecipitation assay using antibodies against BRCA1 and OCT1. (C and D) Ten percent of inputs were used in the last lane. (E) Mutation (MT-1) diminished response of MAD2 promoter to BRCA1 induction. (F) Levels of BRCA1 and MAD2 transcripts (Upper) and protein (Lower) in UBR60 cells 48 h after transfection of BRCA1-specific or control RNAi. (G) Depletion of BRCA1 by BRCA1-specific RNAi, but not control RNAi, abolished response of the MAD2 promoter to BRCA1 induction.

cated that BRCA1 could interact with MAD2 promoter and OCT1 in these cells (Fig. 9 B and C).

Next, we addressed whether the binding between BRCA1 and this site contributes to BRCA1 induction of MAD2 transcription. We introduced the MT-1 mutation (Fig. 5B) into the minimum essential promoter of MAD2 (2,096–2,421, Fig. 5A) and compared its activity with that of the WT promoter. Our data indicated that the mutation significantly decreased induction of MAD2 expression by BRCA1 (Fig. 5E). This assay, however, revealed that BRCA1-mediated induction of MAD2 transcription was moderate, although it was highly reproducible (Fig. 5A and E). One possibility is that the UBR60 cells already have fair amount of endogenous BRCA1 (Fig. 4E and F), which could interact with MAD2 promoter at lower levels as revealed by ChIP assay (+tet, Fig. 4H). Thus, endogenous BRCA1 is likely to contribute to MAD2 expression, obscuring the effect of BRCA1 on MAD2 transcription. To verify this issue, we performed RNA interference (RNAi) study to deplete endogenous BRCA1 in UBR60 cells. We showed that transfection with BRCA1-specific small interfering RNA (siRNA), but not control siRNA, resulted in significant decreases in BRCA1 transcripts and protein (Fig. 5F). BRCA1-specific siRNA also reduced MAD2 transcripts and protein levels (Fig. 5F), which is consistent with the observation that *Brc1* mutant embryos and MEF contained lower levels of Mad2. Next, we checked activities

Fig. 6. Overexpression of MAD2 partially rescues spindle-assembly-checkpoint defect in *Brca1* $\Delta 11/\Delta 11$ MEFs. (A) Western blot analysis showing expression of transfected GFP-MAD2 in *Brca1* $\Delta 11/\Delta 11$ cells. At 48 h after transfection, these cells were incubated with 100 ng/ml nocodazole for various times, as indicated. (B) Trypan-blue-staining analysis showing the decreased dead-cell population in MAD2-transfected cells. (C) FACS assay showing the increased mitotic population in GFP-MAD2-transfected cells compared with GFP-transfected cells. (D) Mad2-GFP-transfection rescues the lagging chromosome phenotype in normal culture condition.

of the MAD2 reporter by luciferase assay after RNAi treatment. Our data indicated that, in the noninducing condition (+tet), expression of the MAD2 reporter decreased ≈ 5 -fold when UBR60 cells were treated with BRCA1-specific RNAi compared with controls (Fig. 5G). The observation that acute knockdown of BRCA1 significantly decreased expression of MAD2 reporter provides evidence, from another angle, that BRCA1 activates the MAD2 promoter. Next, we performed luciferase assay under inducing conditions (–tet) in the UBR60 cells. Our data revealed that in the presence of BRCA1-specific RNAi, expression of BRCA1 (–tet) failed to induce expression of the MAD2 reporter. In control RNAi-treated cells, the induction remained robust, yielding 7- to 8-fold higher level of expression of the MAD2 reporter compared with that of BRCA1-depleted cells (Fig. 5G).

Overexpression of MAD2 in *Brca1* $\Delta 11/\Delta 11$ Cells Partially Rescues the Spindle-Checkpoint Defect. If Mad2 down-regulation in *Brca1* $\Delta 11/\Delta 11$ mutant was a cause for the spindle-checkpoint defect, we would expect that overexpression of Mad2 in *Brca1* $\Delta 11/\Delta 11$ mutant cells should restore or partially restore the spindle checkpoint. To test this possibility, a plasmid carrying GFP-MAD2 was transfected into immortalized *Brca1* $\Delta 11/\Delta 11$ cells, which grow much better and have higher transfection efficiency (40%) than primary mutant MEFs. Expression of exogenous MAD2 could be detected by using an Ab to human MAD2 (Fig. 6A). At 48 h after transfection, nocodazole was added into the culture and maintained for 0–72 h. At each time point, the cells were counted for trypan blue staining (Fig. 6B), or analyzed by FACS after stained with *phospho*-histone H3 Ab to detect mitotic cells (Fig. 6C). As compared with GFP-transfected cells, expression of GFP-MAD2 resulted in a decrease in cell death and an increase in mitotic cells 24–72 h after nocodazole treatment (Fig. 6B and C). We also examined the mitotic status of GFP-positive cells under the microscope and found that 42% of the GFP-transfected cells had normal chromosome segregation, whereas 58% of them had lagging chromosomes. In contrast, 78% of the GFP-MAD2-transfected cells exhibited normal chromosome

segregation, whereas only 22% of them contained lagging chromosomes (Fig. 6D).

Discussion

We have provided evidence that BRCA1 plays a critical role in regulating the spindle checkpoint in both mouse and human cells. Numerous studies, from budding yeast to mammalian cells, indicate that several checkpoint proteins (Mad1–3, Bub1, Bub3, BubR1, Mps1, polo-like kinase, and aurora kinase) act coordinately to prevent anaphase entry when the function of the mitotic spindle is compromised (1, 2). Specifically, these proteins detect unattached kinetochores and prevent cell-cycle progression by inhibiting antigen-presenting cell activity, and therefore, play essential roles in maintaining genome integrity. Our study revealed an altered expression of a number of spindle checkpoint components in *Brcal*^{Δ11/Δ11} MEFs and WT cells carrying acute deletion of *Brcal*, including Mad2, polo-like-Kinase, Bub1, BubR1, and ZW-10. Given the critical role of Mad2 in the spindle checkpoint demonstrated in yeast, *Xenopus* eggs, and mammalian cells (31, 32), we chose to address the possible involvement of Mad2 further. Our data indicated that *Brcal* controls the spindle checkpoint, at least in part, by regulating Mad2. By using a tetracyclin-regulated system to express BRCA1 in UBR60 cells (21), we demonstrated that BRCA1 positively regulates MAD2 by interacting, directly or indirectly, with its promoter. Furthermore, overexpression of MAD2 in mutant cells partially overcame the spindle-checkpoint defects. These observations provide strong evidence that MAD2 plays an important role in mediating functions of BRCA1 in the spindle checkpoint.

Notably, the induction of BRCA1 to MAD2 is moderate under our condition. This evidence may suggest the involvement of additional factors in regulating MAD2 expression. Consistent with this observation, we found that BRCA1 and OCT1 are in the same complex that can be pulled down by the WT oligonucleotide, but not mutant oligonucleotides, contained in the promoter of *MAD2*. This observation suggests that BRCA1 and OCT1 work coordinately in regulating MAD2 expression, although the details remain unclear and warrant further investigation.

BRCA1-associated breast cancer exhibits significantly higher levels of chromosomal abnormalities than sporadic breast cancers (15, 26, 33). The mechanism underlying these alterations can be explained well by the defective spindle checkpoint found in *Brcal* mutant cancer cells. Because of the defect of this checkpoint, *Brcal* ^{$\Delta 11/\Delta 11$} cells would accumulate DNA damage caused by chromosome missegregation and genetic instability. However, based on our finding, the genetic instability would give rise to growth disadvantages for the mutant cells and subject them to apoptosis. However, the genetic instability caused by defective spindle checkpoint could mutate *p53* and other tumor suppressor genes, allowing survival of *Brcal* ^{$\Delta 11/\Delta 11$} cells. We have shown (26, 34) that most (90%) of the tumors derived from *Brcal* conditional knockout in mammary gland lost the WT allele of *p53*. These data are consistent with the finding from human BRCA1-associated breast cancers, which exhibit dramatic chromosome abnormalities and contain more *p53* mutations than sporadic breast cancers (15). These observations indicate that the spindle-checkpoint defect associated with *Brcal* deficiency in combination with inactivation of *p53* plays an essential role in the BRCA1-associated inherited breast cancer.

We have shown that the absence of Brca1 results in the spindle-checkpoint defect that is accompanied by the reduced expression of Mad2 in Brca1 mutant embryos and mutant MEFs. Consistently, induced expression of BRCA1 in UBR60 cells up-regulates MAD2. The defective spindle checkpoint results in chromosome missegregation and premature sister-chromatid separation, leading to p53-mediated apoptosis because p53-deficiency allows mutant cells to survive at expenses of genome integrity. We have shown (13, 16) that p53 deficiency could also rescue embryonic lethality of *Brca1* ^{$\Delta 111/\Delta 111$} embryos and allow them to develop into adulthood with a high risk of tumorigenesis. These findings not only imply that BRCA1 functions in the spindle checkpoint through modulating MAD2 expression, but they also highlight an important role of p53 in repressing BRCA1-associated tumorigenesis.

We thank D. A. Haber (Massachusetts General Hospital, Boston) for UBR60 cells, P. P. Chambon (Institut de Genetique et de Biologie Moleculaire et Cellulaire, Institut National de la Santé et de la Recherche Médicale, Paris) for ERT2 plasmids, and O. Cohen-Fix and members of the laboratory of C.-X.D. for critically reading and commenting on the manuscript.

1. Cleveland, D. W., Mao, Y. & Sullivan, K. F. (2003) *Cell* **112**, 407–421.
2. Yu, H. (2002) *Curr. Opin. Cell Biol.* **14**, 706–714.
3. Sudakin, V., Chan, G. K. & Yen, T. J. (2001) *J. Cell Biol.* **154**, 925–936.
4. Tang, Z., Bharadwaj, R., Li, B. & Yu, H. (2001) *Dev. Cell* **1**, 227–237.
5. Gorbisky, G. J., Chen, R. H. & Murray, A. W. (1998) *J. Cell Biol.* **141**, 1193–1205.
6. Dobles, M., Liberal, V., Scott, M. L., Benezra, R. & Sorger, P. K. (2000) *Cell* **101**, 635–645.
7. Michel, L. S., Liberal, V., Chatterjee, A., Kirchwegger, R., Pasche, B., Gerald, W., Dobles, M., Sorger, P. K., Murty, V. V. & Benezra, R. (2001) *Nature* **409**, 355–359.
8. Deng, C. X. (2001) *Mutat. Res.* **477**, 183–189.
9. Venkitaraman, A. R. (2002) *Cell* **108**, 171–182.
10. Zheng, L., Li, S., Boyer, T. G. & Lee, W. H. (2000) *Oncogene* **19**, 6159–6175.
11. Deng, C. X. (2002) *Environ. Mol. Mutagen.* **39**, 171–177.
12. Deng, C. X. & Wang, R. H. (2003) *Hum. Mol. Genet.* **12**, R113–R123.
13. Xu, X., Qiao, W., Linke, S. P., Cao, L., Li, W. M., Furth, P. A., Harris, C. C. & Deng, C. X. (2001) *Nat. Genet.* **28**, 266–271.
14. Bachelier, R., Xu, X., Wang, X., Li, W., Naramura, M., Gu, H. & Deng, C. X. (2003) *Oncogene* **22**, 528–537.
15. Gasco, M., Yulug, I. G. & Crook, T. (2003) *Hum. Mutat.* **21**, 301–306.
16. Cao, L., Li, W., Kim, S., Brodie, B. G. & Deng, C. X. (2003) *Genes Dev.* **17**, 201–213.
17. Deng, C. X. & Brodie, S. G. (2000) *BioEssays* **22**, 728–737.
18. Vaughn, J. P., Davis, P. L., Jarboe, M. D., Huper, G., Evans, A. C., Wiseman, R. W., Berchuck, A., Iglehart, J. D., Futreal, P. A. & Marks, J. R. (1996) *Cell Growth Differ.* **7**, 711–715.
19. Ruffner, H. & Verma, I. M. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 7138–7143.
20. Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X. W., Harris, C. C., Ried, T. & Deng, C. X. (1999) *Mol. Cell* **3**, 389–395.
21. Harkin, D. P., Bean, J. M., Miklos, D., Song, Y. H., Truong, V. B., Englert, C., Christians, F. C., Ellisen, L. W., Maheswaran, S., Oliner, J. D. & Haber, D. A. (1999) *Cell* **97**, 575–586.
22. Metzger, D., Clifford, J., Chiba, H. & Chambon, P. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 6991–6995.
23. Yang, X., Li, C., Xu, X. & Deng, C. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 3667–3672.
24. Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A. & Brown, M. (2000) *Cell* **103**, 843–852.
25. Nicklas, R. B. (1997) *Science* **275**, 632–637.
26. Brodie, S. G., Xu, X., Qiao, W., Li, W. M., Cao, L. & Deng, C. X. (2001) *Oncogene* **20**, 7514–7523.
27. Ouchi, T., Monteiro, A. N., August, A., Aaronson, S. A. & Hanafusa, H. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 2302–2306.
28. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. & Vogelstein, B. (1993) *Cell* **75**, 817–825.
29. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. & Elledge, S. J. (1993) *Cell* **75**, 805–816.
30. Shah, J. V. & Cleveland, D. W. (2000) *Cell* **103**, 997–1000.
31. Fang, G. (2002) *Mol. Biol. Cell* **13**, 755–766.
32. Wassmann, K., Liberal, V. & Benezra, R. (2003) *EMBO J.* **22**, 797–806.
33. Weaver, Z., Montagna, C., Xu, X., Howard, T., Gadina, M., Brodie, S. G., Deng, C. X. & Ried, T. (2002) *Oncogene* **21**, 5097–5107.
34. Xu, X., Wagner, K. U., Larson, D., Weaver, Z., Li, C., Ried, T., Hennighausen, L., Wynshaw-Boris, A. & Deng, C. X. (1999) *Nat. Genet.* **22**, 37–43.